Contineum Therapeutics Inc. (Class A) (CTNM) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 24% of 52W Range • RSI-14 at 43 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CTNM currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.70) and Max Pain ($9.80) forces dealer call-delta covering toward $18.68.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Contineum Therapeutics Inc. (Class A) (CTNM) advanced +1.97% to $9.33, trading at 24% of its 52-week range ($6.73 – $17.79). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
SAN DIEGO, October 29, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibr
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CTNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CTNM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Contineum Therapeutics Inc. (Class A) (CTNM) ranks #639 by composite RQD confidence (40/100, grade D-) and #501 by equity capitalization ($351.0M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. GALT currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with CTNM at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CTNM
ACTIVE
Contineum Therapeutics Inc. (Class A) | D- | 40/100 | — | — | -29.0% | +1.97% | $351.0M | Benchmark Subject |
| GALT Galectin Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.56% | $355.8M | /galt-vs-ctnm → |
| AVIR Atea Pharmaceuticals Inc. | D- | 40/100 | — | — | -35.0% | +0.94% | $345.7M | /avir-vs-ctnm → |
| CYPH Cypherpunk Technologies Inc. | D- | 40/100 | 71.3x | — | -23.3% | +2.16% | $356.7M | /cyph-vs-ctnm → |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 31/100 | — | — | -35.0% | +0.66% | $345.3M | /arct-vs-ctnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Contineum Therapeutics Inc. (Class A) (CTNM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$60.0M, operating cash flow of -$55.3M, and free cash flow of -$55.5M (-66.5% YoY). On the balance sheet, CTNM closed FY2025 with $276.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$60.0M | -$55.3M | -$55.5M | $276.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$42.3M | -$32.8M | -$33.4M | $212.8M | — |
| FY2023 (FY) | 2023-12-31 | $50.0M | $22.7M | $19.3M | $19.3M | — | — |
As of 2026-11-01, Contineum Therapeutics Inc. (Class A) (NASDAQ: CTNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $9.33 (+1.97% 1D, market cap $351.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTNM ranks #639 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTNM carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.0%. By comparison, GALT (Galectin Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $355.8M) and AVIR (Atea Pharmaceuticals Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $345.7M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).
Per CTNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855175), Contineum Therapeutics Inc. (Class A) generated $0 in revenue, -$60.0M in net income, and -$55.5M in free cash flow against $276.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CTNM last traded at $9.33 (+1.97% on volume of 566,935 shares), positioning the stock -26.54% below its 50-day simple moving average ($12.70) and -31.14% below its 200-day simple moving average ($13.55). Across its 52-week range of $6.73 to $17.79, CTNM sits at the 23.5% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.16 to $10.50).
Why CTNM Stock advanced +1.97% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.